nach oben

CNS Drugs

Erschienen in:

01.10.2009 | Therapy in Practice

Seizures in Patients with Multiple Sclerosis

Epidemiology, Pathophysiology and Management

verfasst von: Brendan J. Kelley, Dr Moses Rodriguez

Erschienen in: CNS Drugs | Ausgabe 10/2009

Einloggen, um Zugang zu erhalten

Abstract

Seizures have been recognized to occur in multiple sclerosis (MS) since early descriptions of the disease. Various studies have attempted to determine the incidence and prevalence of seizures in MS; although they differ in the reported prevalence, seizures do appear to be more common in MS cohorts than in the general population.

The pathological underpinning of seizures in MS remains indeterminate. Cortical and subcortical demyelination and inflammation may explain the increased frequency of seizures in MS, although this hypothetical correlation remains to be proven.

Management of seizures in MS is similar to the management of seizures in other patients. Consideration of the underlying neurological deficits related to MS may be necessary, and dosages of antiepileptic drugs should be adjusted if increased sensitivity to the adverse effects of these agents or interaction with other centrally acting medications is suspected. The prognosis of epilepsy in patients with MS remains uncertain, with some studies suggesting a more favourable prognosis than others.

Leube W. Ueber multiple inselförmige Sklerose des Gehirns und Rückenmarks: Nach Beobachtungen aus der Erlanger medicinischen Klinik. Dtsch Arch Klin Med 1871; 8: 1–29

Ross J. A treatise on the diseases of the nervous system. 2nd ed. London: J & A Churchill, 1883

Poser CM, Brinar VV. Diagnostic criteria for multiple sclerosis: an historical review. Clin Neurol Neurosurg 2004 Jun; 106(3): 147–58PubMedCrossRef

Hoefer P, Guttman S. The electroencephalogram in multiple sclerosis. Trans Am Neurol Assoc 1944; 70: 70–3

Muller R. Studies on disseminated sclerosis with special reference to symptomatology, course and prognosis. Acta Med Scand 1949; 133 Suppl. 222: 1–214

Fuglsang-Frederiksen V, Thygesen P. Seizures and psychopathology in multiple sclerosis. Acta Psychiatr Neurol Scand 1952; 27(1–2): 17–41PubMedCrossRef

Williams Jr GH, Nosik WA, Hunter Jr JA. Convulsions as manifestation of multiple sclerosis. JAMA 1952 Nov 8; 150(10): 990–2CrossRef

Feldman S. Convulsions in multiple sclerosis. J Nerv Ment Dis 1957 Apr–Jun; 125(2): 213–20PubMedCrossRef

Drake Jr WE, Macrae D. Epilepsy in multiple sclerosis. Neurology 1961 Sep; 11: 810–6PubMedCrossRef

10.

Matthews WB. Epilepsy and disseminated sclerosis. Q J Med 1962 Apr; 31: 141–55PubMed

11.

Poser CM. Clinical diagnostic criteria in epidemiological studies of multiple sclerosis. Ann NY Acad Sci 1965 Mar 31; 122: 506–19PubMedCrossRef

12.

Oftedal SI. Multiple sclerosis in Vestfold, Norway. Acta Med Scand 1966; 42 Suppl. 19: 19–26

13.

Hopf HC, Stamatovic AM, Wahren W. Cerebral seizures in multiple sclerosis [in German]. Z Neurol 1970; 198(3): 256–79PubMedCrossRef

14.

Cendrowski W, Majkowski J. Epilepsy in multiple sclerosis. J Neurol Sci 1972 Dec; 17(4): 389–98PubMedCrossRef

15.

Trouillas P, Courjon J. Epilepsy with multiple sclerosis. Epilepsia 1972 Apr; 13(2): 325–33PubMedCrossRef

16.

Ritter G, Poser S. Epilepsy and multiple sclerosis (author’s transl.) [in German]. MMW Munch Med Wochenschr 1974 Nov 8; 116(45): 1983–6PubMed

17.

Shibasaki H, McDonald WI, Kuroiwa Y. Racial modification of clinical picture of multiple sclerosis: comparison between British and Japanese patients. J Neurol Sci 1981 Feb; 49(2): 253–71PubMedCrossRef

18.

Granieri E, Rosati G, Tola R, et al. A descriptive study of epilepsy in the district of Copparo, Italy, 1964–1978. Epilepsia 1983 Aug; 24(4): 502–14PubMedCrossRef

19.

Engelsen BA, Gronning M. Epileptic seizures in patients with multiple sclerosis: is the prognosis of epilepsy underestimated? Seizure 1997 Oct; 6(5): 377–82PubMedCrossRef

20.

Eriksson M, Ben-Menachem E, Andersen O. Epileptic seizures, cranial neuralgias and paroxysmal symptoms in remitting and progressive multiple sclerosis. Mult Scler 2002 Dec; 8(6): 495–9PubMedCrossRef

21.

Kinnunen E, Wikström J. Prevalence and prognosis of epilepsy in patients with multiple sclerosis. Epilepsia 1986 Nov–Dec; 27(6): 729–33PubMedCrossRef

22.

Nicoletti A, Sofia V, Biondi R, et al. Epilepsy and multiple sclerosis in Sicily: a population-based study. Epilepsia 2003 Nov; 44(11): 1445–8PubMedCrossRef

23.

Nyquist PA, Cascino GD, McClelland RL, et al. Incidence of seizures in patients with multiple sclerosis: a population-based study. Mayo Clin Proc 2002 Sep; 77(9): 910–2PubMed

24.

Olafsson E, Benedikz J, Hauser WA. Risk of epilepsy in patients with multiple sclerosis: a population-based study in Iceland. Epilepsia 1999 Jun; 40(6): 745–7PubMedCrossRef

25.

Muller J, Templin A, Sauermann W. Epileptic seizures in multiple sclerosis. Psychiatr Neurol Med Psychol 1986 Sep; 38(9): 497–502

26.

Buttner T, Hornig CR, Dorndorf W. Multiple sclerosis and epilepsy: an analysis of 14 case histories [in German]. Der Nervenarzt 1989 May; 60(5): 262–7PubMed

27.

Ghezzi A, Montanini R, Basso PF, et al. Epilepsy in multiple sclerosis. Eur Neurol 1990; 30(4): 218–23PubMedCrossRef

28.

Moreau T, Sochurkova D, Lemesle M, et al. Epilepsy in patients with multiple sclerosis: radiological-clinical correlations. Epilepsia 1998 Aug; 39(8): 893–6PubMedCrossRef

29.

Sokic DV, Stojsavljevic N, Drulovic J, et al. Seizures in multiple sclerosis. Epilepsia 2001 Jan; 42(1): 72–9PubMedCrossRef

30.

Striano P, Orefice G, Brescia Morra V, et al. Epileptic seizures in multiple sclerosis: clinical and EEG correlations. Neurol Sci 2003 Dec; 24(5): 322–8PubMedCrossRef

31.

Gambardella A, Valentino P, Labate A, et al. Temporal lobe epilepsy as a unique manifestation of multiple sclerosis. Can J Neurol Sci 2003 Aug; 30(3): 228–32PubMed

32.

Giuliani G, Terziani S, Senigaglia AR, et al. Epilepsy in an Italian community as assessed by a survey for prescriptions of antiepileptic drugs: epidemiology and patterns of care. Acta Med Scand 1992 Jan; 85(1): 23–31

33.

Shiraishi K, Higuchi Y, Ozawa K, et al. Clinical course and prognosis of 27 patients with childhood onset multiple sclerosis in Japan. Brain Dev 2005 Apr; 27(3): 224–7PubMedCrossRef

34.

Ozakbas S, Idiman E, Baklan B, et al. Childhood and juvenile onset multiple sclerosis: clinical and paraclinical features. Brain Dev 2003 Jun; 25(4): 233–6PubMedCrossRef

35.

Gusev E, Boiko A, Bikova O, et al. The natural history of early onset multiple sclerosis: comparison of data from Moscow and Vancouver. Clin Neurol Neurosurg 2002 Jul; 104(3): 203–7PubMedCrossRef

36.

Brass SD, Caramanos Z, Santos C, et al. Multiple sclerosis versus acute disseminated encephalomyelitis in childhood. Ped Neurol 2003 Sep; 29(3): 227–31CrossRef

37.

US FDA. Avonex packaging insert [online]. Available from URL: http://www.fda.gov/CDER/foi/label/2003/ifnbbio013103LB.pdf [Accessed 2009 Jan 28]

38.

US FDA. Rebif packaging insert [online]. Available from URL: http://www.fda.gov/cder/foi/label/2003/ifnbser050203LB.pdf [Accessed 2009 Jan 28]

39.

US FDA. Betaseron packaging insert [online]. Available from URL: http://www.fda.gov/cder/foi/label/2003/ifnbchi031403LB.pdf [Accessed 2009 Jan 28]

40.

US FDA. Copaxone packaging insert [online]. Available from URL: http://www.fda.gov/cder/foi/label/2001/20622s15lbl.pdf [Accessed 2009 Jan 28]

41.

Mares P, Tabashidze N. Contradictory effects of GABA-B receptor agonists on cortical epileptic afterdischarges in immature rats. Brain Res Bull 2008 Jan 31; 75(1): 173–8PubMedCrossRef

42.

Leung NY, Whyte IM, Isbister GK. Baclofen overdose: defining the spectrum of toxicity. Emerg Med Australas 2006 Feb; 18(1): 77–82PubMedCrossRef

43.

Peng CT, Ger J, Yang CC, et al. Prolonged severe withdrawal symptoms after acute-on-chronic baclofen overdose. J Toxicol 1998; 36(4): 359–63

44.

Schuele SU, Kellinghaus C, Shook SJ, et al. Incidence of seizures in patients with multiple sclerosis treated with intrathecal baclofen. Neurology 2005 Mar 22; 64(6): 1086–7PubMedCrossRef

45.

Zak R, Solomon G, Petito F, et al. Baclofen-induced generalized nonconvulsive status epilepticus. Ann Neurol 1994 Jul; 36(1): 113–4PubMedCrossRef

46.

Bever Jr CT, Anderson PA, Leslie J, et al. Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial. Neurology 1996 Dec; 47(6): 1457–62PubMedCrossRef

47.

Goodman AD, Brown TR, Cohen JA, et al. Dose comparison trial of sustained-release fampridine in multiple sclerosis. Neurology 2008 Oct 7; 71(15): 1134–41PubMedCrossRef

48.

Goodman AD, Cohen JA, Cross A, et al. Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study. Mult Scler 2007 Apr; 13(3): 357–68PubMedCrossRef

49.

Korenke AR, Rivey MP, Allington DR. Sustained-release fampridine for symptomatic treatment of multiple sclerosis. Ann Pharmacother 2008 Oct; 42(10): 1458–65PubMedCrossRef

50.

Solari A, Uitdehaag B, Giuliani G, et al. Aminopyridines for symptomatic treatment in multiple sclerosis. Cochrane Database Syst Rev 2003; (2): CD001330

51.

Truyen L, Barkhof F, Frequin ST, et al. Magnetic resonance imaging of epilepsy in multiple sclerosis: a case control study. Implications for treatment trials with 4-aminopyridine. Mult Scler 1996 Feb; 1(4): 213–7

52.

Goodman AD, Brown TR, Krupp LB, et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 2009 Feb 28; 373(9665): 732–8PubMedCrossRef

53.

Goodman AD, Brown TR, Cohen JA, et al. Fampridine MS-F202 Study Group: dose comparison trial of sustained-release fampridine in multiple sclerosis. Neurology 2008 Oct 7; 71(15): 1134–41PubMedCrossRef

54.

Primavera A, Gianelli MV, Bandini F. Aphasic status epilepticus in multiple sclerosis. Eur Neurol 1996; 36(6): 374–7PubMedCrossRef

55.

Newman P, Saunders M. A unique case of musicogenic epilepsy. Arch Neurol 1980 Apr; 37(4): 244–5PubMedCrossRef

56.

Striano P, Striano S, Carrieri PB, et al. Epilepsia partialis continua as a first symptom of multiple sclerosis: electrophysiological study of one case. Mult Scler 2003 Mar; 9(2): 199–203PubMedCrossRef

57.

Nyquist PA, Cascino GD, Rodriguez M. Seizures in patients with multiple sclerosis seen at Mayo Clinic, Rochester, Minn, 1990–1998. Mayo Clin Proc 2001 Oct; 76(10): 983–6PubMedCrossRef

58.

Thompson AJ, Kermode AG, Moseley IF, et al. Seizures due to multiple sclerosis: seven patients with MRI correlations. J Neurol Neurosurg Psychiatry 1993 Dec; 56(12): 1317–20PubMedCrossRef

59.

Calabrese M, De Stefano N, Atzori M, et al. Extensive cortical inflammation is associated with epilepsy in multiple sclerosis. J Neurol 2008 Apr; 255(4): 581–6PubMedCrossRef

60.

Awerbuch GI, Verma NP. Periodic lateralized epileptiform discharges in a patient with definite multiple sclerosis. Clin EEG 1987 Jan; 18(1): 38–40

61.

Chabolla DR, Moore JL, Westmoreland BF. Periodic lateralized epileptiform discharges in multiple sclerosis. Electroencephalogr Clin Neurophysiol 1996 Jan; 98(1): 5–8PubMedCrossRef

62.

Gandelman-Marton R, Rabey JM, Flechter S. Periodic lateralized epileptiform discharges in multiple sclerosis: a case report. J Clin Neurophysiol 2003 Apr; 20(2): 117–21PubMedCrossRef

63.

Kidd D, Barkhof F, McConnell R, et al. Cortical lesions in multiple sclerosis. Brain 1999 Jan; 122 (Pt 1): 17–26PubMedCrossRef

64.

Geurts JJ, Bo L, Pouwels PJ, et al. Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology. AJNR Am J Neuroradiol 2005 Mar; 26(3): 572–7PubMed

65.

Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005 Nov; 128 (Pt 11): 2705–12PubMedCrossRef

66.

Pirko I, Lucchinetti CF, Sriram S, et al. Gray matter involvement in multiple sclerosis. Neurology 2007 Feb 27; 68(9): 634–42PubMedCrossRef

67.

Stadelmann C, Albert M, Wegner C, et al. Cortical pathology in multiple sclerosis. Curr Op Neurol 2008 Jun; 21(3): 229–34CrossRef

68.

Zarei M. Clinical characteristics of cortical multiple sclerosis. J Neurol Sci 2006 Jun 15; 245(1–2): 53–8PubMedCrossRef

69.

Zarei M, Chandran S, Compston A, et al. Cognitive presentation of multiple sclerosis: evidence for a cortical variant. J Neurol Neurosurg Psychiatry 2003 Jul; 74(7): 872–7PubMedCrossRef

70.

Kahana E, Leibowitz U, Alter M. Cerebral multiple sclerosis. Neurology 1971 Dec; 21(12): 1179–85PubMedCrossRef

71.

Calabrese M, Atzori M, Bernardi V, et al. Cortical atrophy is relevant in multiple sclerosis at clinical onset. J Neurol 2007 Sep; 254(9): 1212–20PubMedCrossRef

72.

Boggild MD, Williams R, Haq N, et al. Cortical plaques visualised by fluid-attenuated inversion recovery imaging in relapsing multiple sclerosis. Neuroradiology 1996 May; 38Suppl. 1: S10–3PubMedCrossRef

73.

Calabrese M, De Stefano N, Atzori M, et al. Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis. Arch Neurol 2007 Oct; 64(10): 1416–22PubMedCrossRef

74.

Kangarlu A, Bourekas EC, Ray-Chaudhury A, et al. Cerebral cortical lesions in multiple sclerosis detected by MR imaging at 8 Tesla. AJNR Am J Neuroradiol 2007 Feb; 28(2): 262–6PubMed

75.

Zivadinov R, Stosic M, Cox JL, et al. The place of conventional MRI and newly emerging MRI techniques in monitoring different aspects of treatment outcome. J Neurol 2008 Mar; 255 Suppl. 1: 61–74CrossRef

76.

Slapo GD, Lossius MI, Gjerstad L. Poststroke epilepsy: occurrence, predictors and treatment. Expert Rev Neurother 2006 Dec; 6(12): 1801–9PubMedCrossRef

77.

Misra UK, Tan CT, Kalita J. Viral encephalitis and epilepsy. Epilepsia 2008 Aug; 49Suppl. 6: 13–8PubMedCrossRef

78.

Amatniek JC, Hauser WA, DelCastillo-Castaneda C, et al. Incidence and predictors of seizures in patients with Alzheimer’s disease. Epilepsia 2006 May; 47(5): 867–72PubMedCrossRef

Titel: Seizures in Patients with Multiple Sclerosis
Epidemiology, Pathophysiology and Management
verfasst von: Brendan J. Kelley
Dr Moses Rodriguez
Publikationsdatum: 01.10.2009
Verlag: Springer International Publishing
Erschienen in: CNS Drugs / Ausgabe 10/2009
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI: https://doi.org/10.2165/11310900-000000000-00000

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2009

Memantine

Effects of Paroxetine and Sertraline on Low-Density Lipoprotein Cholesterol

Potential Influences of Complementary Therapy on Motor and Non-Motor Complications in Parkinson’s Disease

Antipsychotic Drugs for First-Episode Schizophrenia

Spotlight on Buprenorphine/Naloxone in the Treatment of Opioid Dependence†